Whopping Mortality Benefit in Severe COVID Trial
Treatment with a novel, oral microtubule disruptor significantly reduced the risk of death in hospitalized COVID-19 patients with severe disease, an interim analysis of a phase III study indicated. Mortality at 60 days, the international trial’s primary endpoint, was more than halved in the group assigned to investigational sabizabulin versus those randomized to placebo (20.2% […]